Topics

Genentech Provides Topline Results from Phase II/III Trial With Gantenerumab in Rare Inherited Form of Alzheimer’s Disease

16:16 EST 11 Feb 2020 | Speciality Pharma Journal

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer’s disease (AD). This form of AD, known as autosomal dominant AD …

Original Article: Genentech Provides Topline Results from Phase II/III Trial With Gantenerumab in Rare Inherited Form of Alzheimer’s Disease

NEXT ARTICLE

More From BioPortfolio on "Genentech Provides Topline Results from Phase II/III Trial With Gantenerumab in Rare Inherited Form of Alzheimer’s Disease"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...